Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

bioACTIVATE Bioorthogonal Prodrug Activation at Nanomolar Levels

Coordinator
Technische Universitaet Wien, Austria
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335615

What the project is doing

In the project's own words, from its summary on CORDIS.

Bioorthogonal click-to-release chemistry enables selective bond cleavage in complex biological environments and has emerged as a powerful concept for controlled prodrug activation, most prominently through trans-cyclooctenes and tetrazines. However, established systems face trade-offs between reaction speed, release efficiency, and stability, limiting their application in therapeutic settings. We have discovered a strained cleavable trans-cyclooctene linker that uniquely combines ultrafast click kinetics with high release efficiency and stability.

Compared to current approaches, this TCO exhibits more than 20-fold faster click reactivity, enabling activation under conditions not accessible with existing methods. This advance enables efficient prodrug activation even at nanomolar concentrations, opening new possibilities for targeted therapeutic strategies that remain out of reach. The project will establish proof of concept by developing TCO-caged prodrugs of clinically relevant therapeutics and validating this process using tetrazine triggers, including scaffolds already advanced to clinical trials.

Release kinetics, stability in biological media, and biological activity will be systematically evaluated in solution and cellular models. A central concept of the project is click accumulation, where ultrafast kinetics enable local capture and activation of circulating prodrugs. This will be demonstrated in microfluidic models that mimic vascular flow, providing evidence for efficient activation and therapeutic efficacy at low systemic concentrations.

Supported by an initial patent filing, this technology represents a versatile platform with strong translational potential. It is expected to create new opportunities for safer and more effective targeted therapeutics, with potential applications in prodrug strategies and related delivery systems.

Who is involved

OrganisationCityCountryRole
Technische Universitaet WienWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI